New Adis platform connects the world of drug development
AdisInsight provides window into current evidence on research into new drug treatments
London | Heidelberg, 2 July 2015
Adis, a leading global provider of drug information, has taken a major step forward in its quest to make expertly written drug information more accessible, with the launch of a new platform AdisInsight. The platform presents a unique, joined-up view of current evidence on drug treatments being developed worldwide – how well they work, how safe they are, who is working on them, and how soon they will be available – in a single database.
All of the content in the platform is created as a result of a rigorous curation process undertaken by a team of scientific editors. Multiple global sources including journals, conference proceedings, and government and company websites are monitored continuously to identify any potentially relevant new data. Information is then assessed and verified before being consolidated into concise narratives.
Mike Sumner, Director of Product Management for AdisInsight, explains: “We know that many people access drug information, from academics to regulators, investors to healthcare providers and of course, pharmaceutical manufacturers. These groups may use the information in different ways but they all share a common need – to quickly and easily find accurate data to answer their questions. The AdisInsight platform is designed to help them do just that.”
Adis is a leading global provider of drug information and part of Springer Science+Business Media. For more than 40 years, Adis has been supporting its users through its portfolio of drug-focused medical journals and business intelligence solutions. AdisInsight brings together content from three well-established Adis databases: R&D Insight, Clinical Trials Insight and Pharmacovigilance Insight. The AdisInsight platform is available to preview now at adisinsight.springer.com
Springer Science+Business Media (www.springer.com) is a leading global scientific, technical and medical publisher, providing researchers in academia, scientific institutions and corporate R&D departments with quality content via innovative information products and services. Springer is also a trusted local-language publisher in Europe – especially in Germany and the Netherlands – primarily for physicians and professionals working in healthcare and road safety education. Springer published roughly 2,400 English-language journals and more than 9,000 new books in 2014, and the group is home to the world’s largest STM eBook collection, as well as the most comprehensive portfolio of open access journals. In 2014, Springer Science+Business Media generated sales of approximately EUR 959 million. The group employs some 8,500 individuals across the globe.
Preview platform of AdisInsight
Shane Canning | Springer | Corporate Communications
tel +44 203 192 2243 | email@example.com